Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
justbaseball25
justbaseball25 Jun. 25 at 2:26 PM
what the chances $FBIOP is reinstated this yr?
3 · Reply
itsthrillhouse
itsthrillhouse Jun. 23 at 1:58 PM
$FBIOP question for the sophisticated here. Chance they are delaying reinstatement until global issues have a period of stability? In other words, they may want to be sure that the commons will be more likely to get a big bump on the reinstatement signal, and they will therefore be able to hit the ATM at a better high and with more consistency. Certainly no secondary could be successful/useful until then. Just searching for Occam's razor in why these haven't been restored, with what seems like a potentially bright horizon.
3 · Reply
makrodimutross
makrodimutross Jun. 18 at 5:57 PM
$FBIOP Alan W is right again, and for the life of me, I cannot understand why the board of directors at Fortress have not made it the first order of business after the AGM to reinstate the preferred share dividends. It is lunacy that they are unwilling to accept that the common shares are in the toilet BECAUSE the debt is currently in minor doubt. They need continued access to capital markets, unless they are SO CONFIDENT that they will no longer require any part of their baby shelf, or any future equity raises. But, if the above were true, there wouldn't be a cap on the FBIO commons.
2 · Reply
Kconn52
Kconn52 Jun. 18 at 5:30 PM
$FBIOP they won't be rushing to pay the deferred dividends. FBIOP preferred stock does not earn interest on deferred dividend payments. The biggest incentive to restore the dividend is that $FBIO is effectively locked out of the public capital markets as long as they are in default. At some point fairly soon I predict they will want the flexibility to tap the market even if they don't need the capital.
2 · Reply
makrodimutross
makrodimutross Jun. 18 at 5:05 PM
$FBIOP market looks disappointed that the directors meeting after the agm revealed no progress towards dividend reinstatement. Must be waiting for the PRV.
1 · Reply
justbaseball25
justbaseball25 Jun. 17 at 1:40 PM
my best trades the last few months of selling. $ gmlpf at 9.50 and 7.50. $OXLC at 4.77 $FATBP at 9. $FBIOP at 14-17. $PSEC in 4.70s id be down about 25+K if i kept these. being scared won this time
2 · Reply
makrodimutross
makrodimutross Jun. 16 at 6:53 PM
$FBIOP $FBIO Shareholders don't make decisions like this. Directors do. Once the BOD is elected by the shareholders at the AGM, the chairman of the board will likely hold a directors meeting to discuss such things. Minutes of directors meetings are generally considered confidential, and not released as public information. Decisions made at directors meetings often put members of the BOD in posession of non-public information, so they will not be permitted to engage in open market securities transactions until the NPI is published.
1 · Reply
Kconn52
Kconn52 Jun. 15 at 10:30 PM
$FBIOP wondering if they decide to reinstate dividends on Tuesday...
1 · Reply
Zellchair
Zellchair Jun. 12 at 10:25 AM
$FBIO $FBIOP Please! Read the Disclaimer and Risk in this review before considering an investment in Fortress etc etc etc... https://zellchair.substack.com/p/fortress-biotech-preferred-fbiop
1 · Reply
Zellchair
Zellchair Jun. 12 at 10:12 AM
$FBIO $FBIOP Minimum Net Sales Test Regarding the TTM sales of $57.5M for Journey Medical in Q3 2025, you need to remember that it is currently almost there ($13.1 + $12.0 + $14.6 + $14.9 = $54.6 million), and then they have two full quarters that will add EMROSI, plus we are entering a more favorable season for QBREXZA. It's also important to remember that Journey doesn't need to grow by specifically $7.5M a quarter if you're starting at a higher plateau already (which Journey will do, unless sales fail completely in Q2 and Q3). Milestones/royalties from QBREXZA in Asia will also increase and you should maybe also be able to expect one or more sales deals outside the US for Journey before the $80M cap in Q2 2026. The Liquidity Requirement $7M is the basic requirement for cash on hand if the loan is currently around $35M ($7M applies when the loan is $25M-$50M). Below $25M it is moved down to $5M, below $10M in the loan the requirements for both MNST above and TLR disappear completely.
0 · Reply
Latest News on FBIOP
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 3 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO


Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 2 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO


Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 6 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO


justbaseball25
justbaseball25 Jun. 25 at 2:26 PM
what the chances $FBIOP is reinstated this yr?
3 · Reply
itsthrillhouse
itsthrillhouse Jun. 23 at 1:58 PM
$FBIOP question for the sophisticated here. Chance they are delaying reinstatement until global issues have a period of stability? In other words, they may want to be sure that the commons will be more likely to get a big bump on the reinstatement signal, and they will therefore be able to hit the ATM at a better high and with more consistency. Certainly no secondary could be successful/useful until then. Just searching for Occam's razor in why these haven't been restored, with what seems like a potentially bright horizon.
3 · Reply
makrodimutross
makrodimutross Jun. 18 at 5:57 PM
$FBIOP Alan W is right again, and for the life of me, I cannot understand why the board of directors at Fortress have not made it the first order of business after the AGM to reinstate the preferred share dividends. It is lunacy that they are unwilling to accept that the common shares are in the toilet BECAUSE the debt is currently in minor doubt. They need continued access to capital markets, unless they are SO CONFIDENT that they will no longer require any part of their baby shelf, or any future equity raises. But, if the above were true, there wouldn't be a cap on the FBIO commons.
2 · Reply
Kconn52
Kconn52 Jun. 18 at 5:30 PM
$FBIOP they won't be rushing to pay the deferred dividends. FBIOP preferred stock does not earn interest on deferred dividend payments. The biggest incentive to restore the dividend is that $FBIO is effectively locked out of the public capital markets as long as they are in default. At some point fairly soon I predict they will want the flexibility to tap the market even if they don't need the capital.
2 · Reply
makrodimutross
makrodimutross Jun. 18 at 5:05 PM
$FBIOP market looks disappointed that the directors meeting after the agm revealed no progress towards dividend reinstatement. Must be waiting for the PRV.
1 · Reply
justbaseball25
justbaseball25 Jun. 17 at 1:40 PM
my best trades the last few months of selling. $ gmlpf at 9.50 and 7.50. $OXLC at 4.77 $FATBP at 9. $FBIOP at 14-17. $PSEC in 4.70s id be down about 25+K if i kept these. being scared won this time
2 · Reply
makrodimutross
makrodimutross Jun. 16 at 6:53 PM
$FBIOP $FBIO Shareholders don't make decisions like this. Directors do. Once the BOD is elected by the shareholders at the AGM, the chairman of the board will likely hold a directors meeting to discuss such things. Minutes of directors meetings are generally considered confidential, and not released as public information. Decisions made at directors meetings often put members of the BOD in posession of non-public information, so they will not be permitted to engage in open market securities transactions until the NPI is published.
1 · Reply
Kconn52
Kconn52 Jun. 15 at 10:30 PM
$FBIOP wondering if they decide to reinstate dividends on Tuesday...
1 · Reply
Zellchair
Zellchair Jun. 12 at 10:25 AM
$FBIO $FBIOP Please! Read the Disclaimer and Risk in this review before considering an investment in Fortress etc etc etc... https://zellchair.substack.com/p/fortress-biotech-preferred-fbiop
1 · Reply
Zellchair
Zellchair Jun. 12 at 10:12 AM
$FBIO $FBIOP Minimum Net Sales Test Regarding the TTM sales of $57.5M for Journey Medical in Q3 2025, you need to remember that it is currently almost there ($13.1 + $12.0 + $14.6 + $14.9 = $54.6 million), and then they have two full quarters that will add EMROSI, plus we are entering a more favorable season for QBREXZA. It's also important to remember that Journey doesn't need to grow by specifically $7.5M a quarter if you're starting at a higher plateau already (which Journey will do, unless sales fail completely in Q2 and Q3). Milestones/royalties from QBREXZA in Asia will also increase and you should maybe also be able to expect one or more sales deals outside the US for Journey before the $80M cap in Q2 2026. The Liquidity Requirement $7M is the basic requirement for cash on hand if the loan is currently around $35M ($7M applies when the loan is $25M-$50M). Below $25M it is moved down to $5M, below $10M in the loan the requirements for both MNST above and TLR disappear completely.
0 · Reply
Zellchair
Zellchair Jun. 12 at 10:04 AM
$FBIO $FBIOP With Checkpoint sold, CUTX-101 in the hands of Sentynl/Zydus, Dotinurad (Urica) in the hands of Crystalys, Mustang with $14.23M in cash and on pause more or less until Q4 2025-Q1 2026, Helocytes which has received several grants for its studies, Avenue, Oncogenuity & Cellvation low activity since before, the capital need is not that great in the near future anyway.
0 · Reply
Zellchair
Zellchair Jun. 12 at 10:02 AM
$FBIO $FBIOP The requirement for $25 million in cash under Section 9.05 applies to specific investments such as loans and capital contributions to subsidiaries, not to the dividend payments on preferred stock FBIOP mentioned in Section 9.06(g). However, dividends for Fortress subsidiaries are limited under this $25M requirement (perhaps you misunderstood here), but that wouldn't have been on option anyway. Therefore, as long as no "Event of Default" (read P.70) exists, Fortress can pay dividends on its existing preferred stock under the terms of Section 9.06(g) without meeting the $25M cash requirement for investments. Regarding the requirement for $25 million for investments Fortress had cash and cash equivalents of $91.3 million (all subsidiaries), of which $19.5 million relates to Fortress and private subsidiaries primarily funded by Fortress in Q1. This before the Checkpoint sale which adds $28M.
0 · Reply
Zellchair
Zellchair Jun. 11 at 9:57 PM
$FBIO $FBIOP Past bedtime here, but just want to point out that this is not true. Read the entire texts, both the "CREDIT AGREEMENT" (Exhibit 10.34) between Fortress and Oaktree and the latest Annual Report 2025. If you still don't understand, focus extra on the entire 9.05-9.06 (P.64-66) in CA and the 2024 Oaktree Note in AR (F-29, F-30 P.147-148).
3 · Reply
thesaltier1
thesaltier1 Jun. 11 at 2:58 PM
$FBIOP Funny now $FBIO is running and $FBIOP is lagging
2 · Reply
makrodimutross
makrodimutross Jun. 9 at 8:59 PM
$FBIO $FBIOP $DERM If you were on the fence about Emrosi becoming "Standard of Care" due to efficacy alone, now you must be firmly on the right side of the fence due to the new black box warning for Oracea. the L goes to Galderma, and the W to Journey for this one.
0 · Reply
makrodimutross
makrodimutross Jun. 9 at 8:56 PM
$FBIO $FBIOP $DERM https://medshadow.org/fda-side-effects-update-tetracycline-antibiotics-skin-reactions-new-rinvoq-warnings-for-gca/ "Drugs in the tetracycline class now carry updated safety labels warning of a serious skin reaction known as fixed drug eruptions (FDE), a form of hypersensitivity that causes rashes or blistering, typically recurring in the same spot each time the drug is taken. With an FDE reaction, skin rashes or blistering worsen each subsequent time the drug is used. A very severe variant of FDE is “generalized bullous fixed drug eruption” (GBFDE), which can be life-threatening. If severe skin reactions occur, patients are advised to discontinue the medicine immediately and seek medical help. These label changes were made in response to an FDA letter (here is one example) sent in December 2024 notifying drug sponsors that the required safety information should be added to the drug labels. Two of the tetracycline antibiotics in this update (Doryx and Oracia) also have new warnings about psychiatric adverse events."
2 · Reply
Sawnchey
Sawnchey Jun. 9 at 12:52 PM
$DERM $FBIO $FBIOP Good to see Emrosi getting sone press! They also published the segment on Youtube, so if you want to support advertising by getting the algorithm bump it, be sure to watch the full 6 minute runtime and give the video a like! The more Youtube hits those metrics, the more it will push the video. https://youtu.be/seMmi4XZsyY?si=_zlR9xVSQp8fG-Eg
0 · Reply
Zellchair
Zellchair Jun. 9 at 10:36 AM
$FBIO $FBIOP More this morning. E @ T B A w O.A. & M.W.
1 · Reply
Zellchair
Zellchair Jun. 8 at 4:37 PM
$FBIO $FBIOP However, that doesn't mean you can be lazy if you put a larger amount at stake like me. But fair enough, if it's "coffee money" in relation to your importance to your investing or life, then I understand the ignorance more. But, and this is important in relation to my point with the post: If it is of such little importance, why are you actively writing here? I think that for most people who have written here regularly (like me), Fortress has a significant part of one's invested money (true for me), but perhaps not always equal importance to one's total financial situation (there Fortress has significantly less impact for me). And as I wrote and stick to: Those who write here demonstrably do not have a good grasp of what is happening. Because it's impossible to fool me that if you're sitting on the latest month's news and are active here, that you wouldn't share this good news further here. Especially if they haven't been mentioned before.
0 · Reply
Zellchair
Zellchair Jun. 8 at 4:28 PM
$FBIO $FBIOP Good point below. Yes, diversification is one of Fortress' strengths. And no, there is no individual commercial or clinical asset "death", at its importance today, that would make me sell Fortress altogether at todays valuation. However, I might reduce my holdings, in such a hypothetical outcome. But more hypothetical, if you don't know the current or future importance of an asset, and its news circle from its potential competitors, you will blindly follow that stock down like a dark elevator that drops. In Fortress' case, you most likely not, like many other cases in the sector with one clinical product (or a couple but based on the same mechanism often), fall to the basement, but rather a floor or two. Much of that "lifeline" is what caught my interest and maintains my conviction, when combined with the management's history.
1 · Reply
Zellchair
Zellchair Jun. 8 at 2:36 PM
$FBIO $FBIOP Why am I writing this again? Because there are a number of positive events/news in recent weeks, which in my opinion, have a large part to explain why FBIO/FBIOP share prices here have increased of late. So why the warning? No one has written about them here, not even touched on them. Now there have been positive outcomes, next time they may have negative events... You can't expect Fortress, in a hypothetical scenario, to tell you directly that a competitor has come up with stronger data and that they would essentially "kill" one of their own assets. That responsibility falls on you (good luck). I don't have anywhere near all the knowledge here, on the contrary I'm often wrong, but, at least I try. All active (with proof of the last month) people on this board just want to sail along, with the tailwind, without being prepared if there is a headwind one day... https://stocktwits.com/Zellchair/message/616365586
1 · Reply
Zellchair
Zellchair Jun. 8 at 2:22 PM
$FBIO $FBIOP Checked and will not be able to write/share new information here or on Substack until possibly Q4 starts (2025-10-01) at the earliest. My usual general recommendation, which tends to provoke in relation to my stated view and position, is: Continuously do your homework, and, if you are not prepared to do it in the individual stock, sell it. This is all the more true in this industry with many asymmetric outcomes. It does not have to mean that you need to be right every time, but you need to at least have the background to make decisions around.
0 · Reply